Susquehanna International Group
FDMT icon

Susquehanna International Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Susquehanna International Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$330K Buy
35,400
+18,500
+109% +$161K ﹤0.01% 10668
2025
Q4 		$127K Buy
+16,900
New +$171K ﹤0.01% 11309
2024
Q4 		– Sell
-16,500
Closed -$178K – 12494
2024
Q3 		$178K Sell
16,500
-26,400
-62% -$438K ﹤0.01% 10575
2024
Q2 		$900K Buy
42,900
+21,100
+97% +$529K ﹤0.01% 6837
2024
Q1 		$695K Sell
21,800
-90,400
-81% -$2.31M ﹤0.01% 7716
2023
Q4 		$2.27M Buy
112,200
+95,500
+572% +$1.26M ﹤0.01% 5098
2023
Q3 		$213K Sell
16,700
-400
-2% -$6.69K ﹤0.01% 10100
2023
Q2 		$309K Sell
17,100
-72,500
-81% -$1.33M ﹤0.01% 9375
2023
Q1 		$1.54M Buy
89,600
+55,200
+160% +$1.07M ﹤0.01% 5746
2022
Q4 		$764K Buy
+34,400
New +$531K ﹤0.01% 6773
2022
Q1 		– Sell
-12,100
Closed -$265K – 13261
2021
Q4 		$265K Buy
+12,100
New +$297K ﹤0.01% 10779

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's FDMT Position: Q1 2026 in Review

Susquehanna International Group reduced its 4D Molecular Therapeutics (FDMT) stake by 1.4% in Q1 2026, selling an estimated $15.5K and leaving 124,228 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #7501.

Susquehanna International Group first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.35M in Q1 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Susquehanna International Group held 124,228 shares of 4D Molecular Therapeutics worth $1.16M as of Q1 2026.
  • Susquehanna International Group sold 1,785 4D Molecular Therapeutics shares in Q1 2026, an estimated $15.5K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7501 holding.
  • Susquehanna International Group first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Susquehanna International Group's 4D Molecular Therapeutics position peaked at $1.35M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.